87 related articles for article (PubMed ID: 23061485)
21. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Giri S; Hamdeh S; Bhatt VR; Schwarz JK
J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Chen YB; Li S; Lane AA; Connolly C; Del Rio C; Valles B; Curtis M; Ballen K; Cutler C; Dey BR; El-Jawahri A; Fathi AT; Ho VT; Joyce A; McAfee S; Rudek M; Rajkhowa T; Verselis S; Antin JH; Spitzer TR; Levis M; Soiffer R
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2042-8. PubMed ID: 25239228
[TBL] [Abstract][Full Text] [Related]
23. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.
Wander SA; Levis MJ; Fathi AT
Ther Adv Hematol; 2014 Jun; 5(3):65-77. PubMed ID: 24883179
[TBL] [Abstract][Full Text] [Related]
24. Crenolanib is a selective type I pan-FLT3 inhibitor.
Smith CC; Lasater EA; Lin KC; Wang Q; McCreery MQ; Stewart WK; Damon LE; Perl AE; Jeschke GR; Sugita M; Carroll M; Kogan SC; Kuriyan J; Shah NP
Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5319-24. PubMed ID: 24623852
[TBL] [Abstract][Full Text] [Related]
25. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
26. New agents: great expectations not realized.
Lancet JE
Best Pract Res Clin Haematol; 2013 Sep; 26(3):269-74. PubMed ID: 24309529
[TBL] [Abstract][Full Text] [Related]
27. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
Eriksson A; Kalushkova A; Jarvius M; Hilhorst R; Rickardson L; Kultima HG; de Wijn R; Hovestad L; Fryknäs M; Öberg F; Larsson R; Parrow V; Höglund M
Biochem Pharmacol; 2014 Jan; 87(2):284-91. PubMed ID: 24200998
[TBL] [Abstract][Full Text] [Related]
28. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
29. Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
Wolleschak D; Schalk E; Krogel C; Schnoeder TM; Luehr H; Jentsch-Ullrich K; Fischer T; Heidel FH
J Hematol Oncol; 2013 Jun; 6():39. PubMed ID: 23759001
[TBL] [Abstract][Full Text] [Related]
30. Novel therapies for children with acute myeloid leukaemia.
Moore AS; Kearns PR; Knapper S; Pearson AD; Zwaan CM
Leukemia; 2013 Jul; 27(7):1451-60. PubMed ID: 23563239
[TBL] [Abstract][Full Text] [Related]
31. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
32. Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael E; Georgiou G; Benetatos L; Briasoulis E
Am J Blood Res; 2013; 3(1):29-51. PubMed ID: 23358589
[TBL] [Abstract][Full Text] [Related]
33. [Successful treatment with sorafenib for primary refractory acute monoblastic leukemia with FLT3-ITD].
Takahashi N; Kawakami T; Sato H; Onoda T; Kanno M; Mitsui T; Hayasaka K
Rinsho Ketsueki; 2012 Nov; 53(11):1932-6. PubMed ID: 23257676
[TBL] [Abstract][Full Text] [Related]
34. A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
Weisberg E; Sattler M
Haematologica; 2012 Nov; 97(11):1620-1. PubMed ID: 23125243
[No Abstract] [Full Text] [Related]
35. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
36. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia:
Bazarbachi A; Labopin M; Battipaglia G; Djabali A; Forcade E; Arcese W; Socié G; Blaise D; Halter J; Gerull S; Cornelissen JJ; Chevallier P; Maertens J; Schaap N; El-Cheikh J; Esteve J; Nagler A; Mohty M
Clin Hematol Int; 2019 Mar; 1(1):58-74. PubMed ID: 34595412
[TBL] [Abstract][Full Text] [Related]
38. Management of the Older Patient with Myelodysplastic Syndrome.
Shallis RM; Zeidan AM
Drugs Aging; 2021 Sep; 38(9):751-767. PubMed ID: 34342860
[TBL] [Abstract][Full Text] [Related]
39. Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments.
Pagliuca S; Gurnari C; Visconte V
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668555
[TBL] [Abstract][Full Text] [Related]
40. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with
Bazarbachi A; Bug G; Baron F; Brissot E; Ciceri F; Dalle IA; Döhner H; Esteve J; Floisand Y; Giebel S; Gilleece M; Gorin NC; Jabbour E; Aljurf M; Kantarjian H; Kharfan-Dabaja M; Labopin M; Lanza F; Malard F; Peric Z; Prebet T; Ravandi F; Ruggeri A; Sanz J; Schmid C; Shouval R; Spyridonidis A; Versluis J; Vey N; Savani BN; Nagler A; Mohty M
Haematologica; 2020 Jun; 105(6):1507-1516. PubMed ID: 32241850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
